Ausgabe 4/2018
Inhalt (26 Artikel)
Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
W. Ryan Powell, Cindy L. Christiansen, Donald R. Miller
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
Valentin Demmel, Anne Sandberg-Schaal, Jacob B. Jacobsen, Georg Golor, Jonas Pettersson, Anne Flint
Agreement Between the JCDCG, Revised NCEP-ATPIII, and IDF Definitions of Metabolic Syndrome in a Northwestern Chinese Population
Fei Sun, Bin Gao, Li Wang, Ying Xing, Jie Ming, Jie Zhou, Jianfang Fu, Xiaomiao Li, Shaoyong Xu, Guocai Liu, Qiuhe Ji
Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
Hiroshi Nishiyama, Tomotaka Shingaki, Yumi Suzuki, Liza L. Ilag
Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
Gian Paolo Fadini, Daniele Bottigliengo, Federica D’Angelo, Franco Cavalot, Antonio Carlo Bossi, Giancarlo Zatti, Ileana Baldi, Angelo Avogaro, Agostino Consoli, Gloria Formoso, Giovanni Grossi, Achiropita Pucci, Giorgio Sesti, Francesco Andreozzi, Giuseppe Capobianco, Adriano Gatti, Riccardo Bonadonna, Ivana Zavaroni, Alessandra Dei Cas, Giuseppe Felace, Patrizia Li Volsi, Raffaella Buzzetti, Gaetano Leto, Gian Pio Sorice, Paola D’Angelo, Susanna Morano, Antonio Carlo Bossi, Edoardo Duratorre, Ivano Franzetti, Paola Silvia Morpurgo, Emanuela Orsi, Fabrizio Querci, Massimo Boemi, Federica D’Angelo, Massimiliano Petrelli, Gianluca Aimaretti, Ioannis Karamouzis, Franco Cavalot, Giuseppe Saglietti†, Giuliana Cazzetta, Silvestre Cervone, Eleonora Devangelio, Olga Lamacchia, Salvatore Arena, Antonino Di Benedetto, Lucia Frittitta, Carla Giordano, Salvatore Piro, Manfredi Rizzo, Roberta Chianetta, Carlo Mannina, Roberto Anichini, Giuseppe Penno, Anna Solini, Bruno Fattor, Enzo Bonora, Massimo Cigolini, Annunziata Lapolla, Nino Cristiano Chilelli, Maurizio Poli, Natalino Simioni, Vera Frison, Carmela Vinci
Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
Chakrapani Balijepalli, Rohan Shirali, Prashanth Kandaswamy, Anastasia Ustyugova, Egon Pfarr, Søren S. Lund, Eric Druyts
Long-Term Effect of the Color Record Method in Self-Monitoring of Blood Glucose on Metabolic Parameters in Type 2 Diabetes: A 2-Year Follow-up of the Color IMPACT Study
Akiko Nishimura, Shin-ichi Harashima, Kiminori Hosoda, Nobuya Inagaki
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
Maria J. Pereira, Per Lundkvist, Prasad G. Kamble, Joey Lau, Julian G. Martins, C. David Sjöström, Volker Schnecke, Anna Walentinsson, Eva Johnsson, Jan W. Eriksson
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Kristin Cecilie Carlsson Petri, Steen Hvass Ingwersen, Anne Flint, Jeppe Zacho, Rune Viig Overgaard
Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
Hisamitsu Ishihara, Susumu Yamaguchi, Ikko Nakao, Taishi Sakatani
There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study
Tomoe Kinoshita, Masashi Shimoda, Junpei Sanada, Yoshiro Fushimi, Yurie Hirata, Shintaro Irie, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Kenji Kohara, Fuminori Tatsumi, Shinji Kamei, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials
Annaswamy Raji, Jianmin Long, Raymond L. H. Lam, Edward A. O’Neill, Samuel S. Engel
Cerebral Biochemical Effect of Pregabalin in Patients with Painful Diabetic Neuropathy: A Randomized Controlled Trial
Mats De Jaeger, Lisa Goudman, Peter Van Schuerbeek, Johan De Mey, Bart Keymeulen, Raf Brouns, Maarten Moens
Contribution of BHG and PPHG to Overall Hyperglycemia in T2DM Patients Treated with LM25 and LM50: Post Hoc Analysis of a Randomized Crossover Trial
Wei Li, Fan Ping, Lingling Xu, Huabing Zhang, Yaxiu Dong, Hongmei Li, Qi Sun, Yuxiu Li
Turkish Insulin Injection Techniques Study: Complications of Injecting Insulin Among Turkish Patients with Diabetes, Education They Received, and the Role of Health Care Professional as Assessed by Survey Questionnaire
Selcuk Dagdelen, Oguzhan Deyneli, Nermin Olgun, Zeynep Osar Siva, Mehmet Sargin, Sükrü Hatun, Mustafa Kulaksizoglu, Ahmet Kaya, Cansu Aslan Gürlek, Laurence J. Hirsch, Kenneth W. Strauss
Turkish Insulin Injection Technique Study: Population Characteristics of Turkish Patients with Diabetes Who Inject Insulin and Details of Their Injection Practices as Assessed by Survey Questionnaire
Selcuk Dagdelen, Oguzhan Deyneli, Nermin Olgun, Zeynep Osar Siva, Mehmet Sargin, Sükrü Hatun, Mustafa Kulaksizoglu, Ahmet Kaya, Cansu Aslan Gürlek, Laurence J. Hirsch, Kenneth W. Strauss
Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial
Ameer Khowaja, Jamil B. Alkhaddo, Zaighum Rana, Lisa Fish
Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries
Goran Petrovski, Dashamir Gjergji, Aleksandra Grbic, Blazenko Vukovic, Mitja Krajnc, Natasa Grulovic
The Associations between Paraoxonase 1 L55M/Q192R Genetic Polymorphisms and the Susceptibilities of Diabetic Macroangiopathy and Diabetic Microangiopathy: A Meta-Analysis
Chenfang Wu, Diling Wu, Minjie Lin, Yanjun Zhong
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
Eugene Han, Ari Kim, Sung Jae Lee, Je-Yon Kim, Jae Hyeon Kim, Woo Je Lee, Byung-Wan Lee
Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes
Chantal Mathieu, Doina Catrinoiu, Aurelian Emil Ranetti, Eva Johnsson, Lars Hansen, Hungta Chen, Ricardo Garcia-Sanchez, Nayyar Iqbal, Aleksander Celiñski
Successful Management of Poorly Controlled Type 2 Diabetes with Multidisciplinary Neurobehavioral Rehabilitation: A Case Report and Review
Zhihui Deng, John Davis, Flor Muniz-Rodriguez, Fran Richardson
Correction to: Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ)
Hitoshi Ishii, Koki Shin, Takahiro Tosaki, Tatsuya Haga, Yoshiki Nakajima, Toshihiko Shiraiwa, Nobuaki Watanabe, Miyuki Koizumi, Hiroki Nakajima, Sadanori Okada, Tsuyoshi Mashitani, Takako Mohri, Yasuhiro Akai
Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
Ian J. Neeland, Darren K. McGuire, Björn Eliasson, Martin Ridderstråle, Cordula Zeller, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen